S-1452

S-1452 is a **novel, orally active, potent thromboxane A2 receptor antagonist** developed for the inhibition of thromboxane A2 activity, which is implicated in platelet aggregation and arterial tone regulation. It has been studied in animal models for the prevention and attenuation of postischemic brain injury, cerebral infarction, and platelet aggregation. S-1452 administration decreased infarct areas in cerebral ischemia models and reduced postischemic brain edema, suggesting protective effects in ischemic stroke. The compound acts by blocking thromboxane A2 receptors, thereby reducing downstream effects such as platelet aggregation and vascular constriction. S-1452 is chemically related to norbornene derivatives and is available as a calcium salt for improved stability and bioavailability[1][3].

Other names

S-1452S1452S 1452d-s-145 Cad-s145 Cad-s 145 Ca(+)-S-145S-1452 calcium saltS1452 calcium saltS 1452 calcium salt